Dazukibart

Dazukibart (PF-06823859) is a potent, selective humanized IgG1 neutralizing monoclonal antibody that targets interferon β (IFNβ) . Dazukibart can be used in the study of moderate to severe dermatomyositis[1].

Product Specifications

CAS Number

[2639474-65-8]

Product Name Alternative

PF-06823859

UNSPSC

12352203

Hazard Statement

H302, H315, H319, H335

Target

IFNAR

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/dazukibart.html

Purity

99.9

Solubility

10 mM in DMSO

Smiles

[Dazukibart]

Molecular Weight

(145.36 kDa)

Precautions

H302, H315, H319, H335

References & Citations

[1]Fiorentino D, et al. Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2025 Jan 11;405 (10473) :137-146.